AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AstraZeneca, in collaboration with Parexel International, is conducting a Phase I study titled ‘A Multiple Centre, Randomised, Open-label, Parallel Group, Phase I Pharmacokinetic Comparability Study of Tozorakimab Administered Using an Accessorised Prefilled Syringe (APFS) or an Autoinjector (AI) in Healthy Volunteers.’ The study aims to compare the pharmacokinetic profiles of tozorakimab when administered via two different devices, an autoinjector and an accessorised prefilled syringe, in healthy participants.
The study tests two interventions: the experimental use of an autoinjector (AI) device and the active comparator, an accessorised prefilled syringe (APFS) device, both delivering a single subcutaneous dose of the drug Tozorakimab. The purpose is to determine the most effective delivery method.
This is a randomized, open-label, parallel group study with no masking involved, primarily focused on treatment. Participants are randomly assigned to one of the six combinations of devices and injection sites, ensuring a comprehensive analysis of the delivery methods.
The study began on April 7, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on July 7, 2025, indicating ongoing recruitment and progress.
This study could significantly impact AstraZeneca’s market position by potentially enhancing the delivery efficiency of Tozorakimab, thus influencing investor sentiment positively. With ongoing recruitment, the study’s outcomes may also affect competitors focusing on similar pharmacokinetic improvements.
The study is currently recruiting, and further details can be accessed on the ClinicalTrials portal.